SCHEMBL17211803

SCHEMBL17211803

CCOC(=O)CC1(C)Cc2cc(Br)ccc2C1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 1/20 0.44
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
ALDH1A1 P00352 4/20 0.37
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
GAA P10253 2/20 0.36
APAF1 O14727 1/20 0.36
SMAD3 P84022 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
CASP1 P29466 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPK1 P28482 2/20 0.36
BRD4 O60885 1/20 0.36
PIN1 Q13526 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14061841 0.85 TDP2 (0.44) TDP2TSHRHTTALDH1A1KMT2A
SCHEMBL10341539 0.84 SMN1; SMN2 (0.47) TSHRALDH1A1L3MBTL1GAAKDM4E
SCHEMBL10341556 0.83 DGAT1 (0.44) TDP2BRD4
SCHEMBL17460906 0.81 DGAT1 (0.40) TDP2ALDH1A1KMT2AMEN1GAA
SCHEMBL17211801 0.78 SMN1; SMN2 (0.43) HTTALDH1A1KDM4ELMNAMAPT
SCHEMBL28439892 0.75 DGAT1 (0.39) KMT2AMEN1GAAKDM4EHSD17B10
SCHEMBL17195446 0.75 DGAT1 (0.48) ALDH1A1KMT2AL3MBTL1GAABRD4
SCHEMBL14062088 0.74 DGAT1 (0.44)
SCHEMBL17211827 0.73 DGAT1 (0.48) TDP2
SCHEMBL14061713 0.72 SMN1; SMN2 (0.57) ALDH1A1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242929-B2 Compounds as diacylglycerol acyltransferase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-01-26 US disclosed
US-20150307445-A1 Novel Compounds as Diacylglycerol Acyltransferase Inhibitors GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) 2015-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307445-A1 Novel Compounds as Diacylglycerol Acyltransferase Inhibitors DGAT1, DGAT2, LCAT TDP2 3936/4885TSHR 2548/4885HTT 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.